Select Page

Anti-Human IL-2R alpha (CD25) (Basiliximab) – Dylight® 488 – 100 µg

100 μg



ApplicationFC, IF, IHC
ConjugateDyLight® 488
IsotypeHuman IgG1κ
ImmunogenHuman CD25
Species ReactivityHuman, Cynomolgus Monkey, Rhesus Monkey
FormulationThis DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Research AreaCancer, Immunology
Description/BackgroundCD25, a 55 kD type I transmembrane glycoprotein, has been shown to play roles in lymphocyte differentiation, activation, and proliferation. Many resting memory T cells constitutively express IL2Rα. It functions as the receptor for HTLV-1, resulting in its expression on neoplastic cells in adult T cell lymphoma/leukemia. CD25 (sIL-2R) has been used to track disease progression. Some additional clinical applications include Chagas disease, a disease characterized by a decline of CD25 expression on immune cells, and Multiple sclerosis, in which treatments with mAbs target CD25. Anti-Human IL-2R alpha (CD25) (Basiliximab) utilizes the same variable regions from the therapeutic antibody Basiliximab making it ideal for research projects.
Storage TemperatureThis DyLight® 488 conjugate is stable when stored at 2-8°C. Do not freeze.
ProtocolsFC, IF, IHC
Clone NumberHu107
Concentration0.2 mg/ml
Regulatory StatementFor Research Use Only. Not for use in diagnostic procedures.
100 μg